Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news.
Initial studies by BioNTech SE and the regional distributor found no safety concerns with groups of vaccines shipped to Hong Kong, after packaging defects halted the use of the Covid-19 vaccine in the city.
Early decisions did not find the possibility that packaging defects may have been due to environmental factors during long haul transportation, the Hong Kong government said in a statement, without specifying. The government, BioNTech and Shanghai Fosun Pharmaceutical Group Co. aims to complete the investigation within a week, he said.
Hong Kong bans BioNTech on Vial Loose captain, Stains
The city’s vaccination campaign went into overdrive this week when he and nearby Macau suspended photos taken by BioNTech for a time due to packaging deficiencies. The ban risks eroding public confidence in the vaccine, which gave Hong Kong residents an alternative to the one made by Chinese company Sinovac Biotech Ltd.
The deficiencies, which included loose vial caps and colored bottles, affected approximately 1.3 million doses delivered to the financial hub. Around 150,000 people had received BioNTech hits in Hong Kong before they stopped.
Fosun and BioNTech have inspected the entire supply chain, including the sealing process in BioNTech’s German facilities, vaccine packaging, transportation to Hong Kong, logical processing and post-arrival storage. city, as well as inspections at community vaccination centers. They found no “obvious systemic factors” that could have led to the flaws from packaging to use, according to the report.
The companies also said they did not believe the deficiencies were due to cold chain issues and logistic regulation. A randomized study of the remaining vaccine filters with complete packaging found no evidence of leakage.